Huafu Securities released a research report on April 18 stating that it gave Microchip Biotech (688321.SH) a purchase rating. The main reasons for the rating include: 1) the sales peak for sidabendamide hematomas is expected to exceed 1 billion dollars, and sales of solid tumors will increase by more than 2 billion dollars; 2) the release of siglitazide will accelerate after entering medical insurance, and phase III of NASH clinical trials will be launched within 2024. (Mainichi Keizai Shimbun)
华福证券4月18日发布研报称，给予微芯生物（688321.SH）买入评级。评级理由主要包括：1）预计西达本胺血液瘤超10亿销售峰值，实体瘤增加超过20亿销售；2）西格列他钠进医保后放量加快，NASH临床III期2024年内启动。（每日经济新闻）
Huafu Securities released a research report on April 18 stating that it gave Microchip Biotech (688321.SH) a purchase rating. The main reasons for the rating include: 1) the sales peak for sidabendamide hematomas is expected to exceed 1 billion dollars, a
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.